Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2026)

Amylyx Pharmaceuticals' Current Assets history runs 6 years deep, the most recent figure standing at $285.0 million for Q1 2026.

• On a quarterly basis, Current Assets rose 31.87% year-over-year to $285.0 million in Q1 2026; TTM through Mar 2026 was $285.0 million, a 31.87% increase from a year earlier, with the FY2025 full-year figure at $323.7 million, up 70.86% from the prior year.
• Current Assets retreated to $285.0 million in Q1 2026 per AMLX's latest filing, from $323.7 million in the prior quarter.
• Across five years, Current Assets topped out at $464.7 million in Q4 2023 and bottomed at $172.2 million in Q3 2022.
• The 5-year median for Current Assets is $323.7 million (2025), against an average of $311.1 million.
• Across the five-year window, Current Assets soared 264.11% in 2022 and slumped 59.23% in 2024, its largest moves.
• Year by year, Current Assets stood at $382.1 million in 2022, then grew by 21.6% to $464.7 million in 2023, then slumped by 59.23% to $189.4 million in 2024, then surged by 70.86% to $323.7 million in 2025, then slipped by 11.94% to $285.0 million in 2026.
• Per Business Quant, the three latest AMLX Current Assets figures stand at $285.0 million (Q1 2026), $323.7 million (Q4 2025), and $353.4 million (Q3 2025).